Pain News and Research

Latest Pain News and Research

American Diabetes Association issues statement to address diabetes management in LTC facilities

The care of adults over age 65 with type 2 diabetes is a growing concern: the prevalence of diabetes is highest in this age group and is expected to grow as the U.S. population ages, with many needing care at long-term care (LTC) facilities.

3 Feb 2016

Innovative mattresses to stop pressure ulcers: an interview with Mike Hutson

Pressure ulcers are wounds that occur when a continuous pressure or friction is placed on one area of the body, damaging the skin. They occur when pressure stops blood from flowing normally, leading the cells to die and the skin to break down.

3 Feb 2016

FDA approves ZEMBRACESymTouch (sumatriptan succinate) injection for treatment of acute migraines

Dr. Reddy's Laboratories, announced today that the U.S. Food and Drug Administration has approved ZEMBRACESymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens.

3 Feb 2016

Researchers use new method to assess quality of colonoscopies performed in outpatient facilities

Colonoscopies are now a routine preventive diagnostic test for millions of Americans each year. While rates are low, complications like perforation, bleeding, and anesthesia-related heart failure can occur. Yale School of Medicine researchers have now developed a quality measure that uses follow-up hospital visits to track the variation in colonoscopy quality among outpatient facilities.

2 Feb 2016

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.

1 Feb 2016

People with disabilities, caregivers, veterans and healthcare professionals to attend 2016 Abilities Expo

Thousands of people with disabilities, their families, caregivers, seniors, wounded veterans and healthcare professionals are expected to attend Abilities Expo on February 5-7, 2016 at the Los Angeles Convention Center, West Hall A. Admission is free and the new show hours will get attendees home in time to watch the Super Bowl: Friday 11 am to 5 pm, Saturday 10 am to 6 pm and Sunday 10 am to 2 pm.

1 Feb 2016

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

29 Jan 2016

Zika virus threat across the Americas

Yesterday, the World Health Organization (WHO) announced that the Zika virus outbreak in Brazil was “spreading explosively” in the Americas and that as many as four million people could be infected by the end of the year.

29 Jan 2016

Researchers develop new painkiller as strong as morphine but not addictive

Researchers at Tulane University and Southeast Louisiana Veterans Health Care System have developed a painkiller that is as strong as morphine but isn't likely to be addictive and with fewer side effects, according to a new study in the journal Neuropharmacology.

29 Jan 2016

New NYUCD study explores how gene expression initiated in notochord

A new study by basic science researchers in the Department of Basic Science and Craniofacial Biology at New York University College of Dentistry sought to understand how gene expression is initiated in the notochord, the evolutionary and developmental precursor of the backbone.

29 Jan 2016

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo.

29 Jan 2016

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

28 Jan 2016

New technique may reduce need for amputation in patients with critical limb ischemia

A new imaging technique could reduce the need for amputation in patients with critical limb ischemia, according to a study publised today in the scientific journal JACC.

28 Jan 2016

Velano Vascular obtains FDA clearance for modified version of novel blood draw device

Velano Vascular, a medical technology company transforming and enhancing the care experience for hospitalized patients and their practitioners, announced today that the company received U.S. Food and Drug Administration clearance for a modified version of its novel, needle-free blood draw device.

27 Jan 2016

Educational programs, new clinic policies could significantly reduce level of opioid medication

A recent study showed that medical provider training, new clinic policies and efforts to "taper" opioid use for pain treatment could significantly reduce the level of opioid medication that patients used -- a limited but positive step for a nation enmeshed in opioid use, abuse and overdose deaths.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Opioid medication does not improve physical function in patients with neuropathic pain

Opioids such as morphine, codeine and Tylenol 3 can be effective for treating pain, however, a new University of Alberta study finds that patients with neuropathic pain taking opioids report no improvements in physical functioning compared to those who were not prescribed opioids.

25 Jan 2016

Orthocell to present positive data from pilot study of tendon cell treatment at international hip meeting

Regenerative medicine company Orthocell Limited is pleased to announce it will present new positive two year data from a study of its tendon cell treatment for degenerate hip (gluteal) tendons at the 3rd Melbourne International Hip Arthroscopy meeting.

25 Jan 2016

Epidural analgesia has some adverse effects on newborns

Researchers from the University of Granada observed that babies born after epidural analgesia show a small decline in Apgar index values, a quick test applied to newborn babies in order to assess their general health.

25 Jan 2016

Facts associated with Zika virus

As the Zika virus captures headlines across the United States, with its possible link to birth defects and the first cases reported in the U.S. (all traced back to overseas travel), it's an opportune time to review the facts associated with this disease.

22 Jan 2016

Pain News and Research

Latest Pain News and Research

American Diabetes Association issues statement to address diabetes management in LTC facilities

Innovative mattresses to stop pressure ulcers: an interview with Mike Hutson

FDA approves ZEMBRACESymTouch (sumatriptan succinate) injection for treatment of acute migraines

Researchers use new method to assess quality of colonoscopies performed in outpatient facilities

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

People with disabilities, caregivers, veterans and healthcare professionals to attend 2016 Abilities Expo

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Zika virus threat across the Americas

Researchers develop new painkiller as strong as morphine but not addictive

New NYUCD study explores how gene expression initiated in notochord

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

Halaven (eribulin mesylate) approved for treatment of liposarcoma

New technique may reduce need for amputation in patients with critical limb ischemia

Velano Vascular obtains FDA clearance for modified version of novel blood draw device

Educational programs, new clinic policies could significantly reduce level of opioid medication

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Opioid medication does not improve physical function in patients with neuropathic pain

Orthocell to present positive data from pilot study of tendon cell treatment at international hip meeting

Epidural analgesia has some adverse effects on newborns

Facts associated with Zika virus

Forensics and toxicology - Industry Focus eBook eBook

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Pain News and Research

Latest Pain News and Research

Forensics and toxicology - Industry Focus eBook eBook

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in